Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 1;105(10):2358-2367.
doi: 10.3324/haematol.2020.247015.

Multiple myeloma: the (r)evolution of current therapy and a glance into future

Annamaria Gulla  1 , Kenneth C Anderson  1
Affiliations

Multiple myeloma: the (r)evolution of current therapy and a glance into future

Annamaria Gulla et al. Haematologica. .

Abstract

Over the past 20 years, the regulatory approval of several novel agents to treat multiple myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased understanding of MM biology has translated to advances in diagnosis, prognosis, and response assessment, as well as informed the development of targeted and immune agents. Here we provide an overview of the recent progress in MM, and highlight research areas of greatest promise to further improve patient outcome in the future.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overview of the different anti-multiple myeloma (MM) strategies discussed in the review. Purple: strategies designed to directly target MM cell vulnerabilities; we can distinguish those exploiting “lineage dependencies” or “clonal dependencies”. (Center) Strategy targeting “epigenetic modifications” that may broadly affect both lineage and clonal vulnerabilities. (Bottom, yellow) Strategies aiming to disrupt MM-bone marrow microenvironment (BMM) interplay and restore host immunosurveillance. Purple double pointed arrows: MM-related approaches; yellow double pointed arrows: BMM-related approaches. These highlight the fact that one specific treatment, even in case of target therapy, may also affect multiple cellular components/interactions thus amplifying the therapeutic effects. OB: osteoblast; OC: osteoclasts; BMEC: bone marrow endothelial cells; ECM: extracellular matrix; BMSC: bone marrow stromal cells; DC: dendritic cell; pDC: plasmacytoid DC; MDSC: myeloid derived suppressor cells; Treg: regulatory T cell.
Graphical Abstract
Graphical Abstract
See this image and copyright information in PMC

References

    1. National Cancer Institute. Cancer stat facts: myeloma. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed 20 July 2020.
    1. Cowan AJ, Allen C, Barac A, et al. . Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221-1227. - PMC - PubMed
    1. Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016;22(22):5419-5427. - PMC - PubMed
    1. Kumar SK, Rajkumar V, Kyle RA, et al. . Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. - PubMed
    1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-548. - PubMed

Publication types